Clinical studies, like SURMOUNT trials, show that tirzepatide has greater anti-obesity effects than semaglutide, promoting weight and fat mass reduction, appetite suppression, energy expenditure, insulin sensitivity, and glycemic parameters in obese [120] and diabetic patients [121]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.